Although the triggering mechanisms of tissue inflammation and injury in meconium-contaminated lungs are still unclear, there is increasing evidence to suggest a central role for phospholipase A 2 's (PLA 2 ). In fact, elevated PLA 2 activities together with high enzyme concentrations, especially the amount of pancreatic (group I) secretory PLA 2 (PLA 2 -I), have been detected in human meconium and in meconium-contaminated lungs. Recent data from our laboratory further indicate that human pancreatic PLA 2 , introduced in high amounts within aspirated particulate meconium, is a potent inducer of lung tissue inflammatory injury. Our finding of elevated human PLA 2 -I concentrations in plasma during the first hours after intratracheal meconium administration in newborn piglets further suggests that intrapulmonary aspiration of meconium could also have systemic inflammatory and injurious effects. This, however, remains to be studied in further detail.
Aspiration of meconium is known to initiate a complex cascade of pulmonary processes, resulting in progressively increasing pulmonary vascular tone and a rapidly developing inflammatory tissue injury with concomitant surfactant dysfunction in the affected lungs. 1, 2 Although the critical role of pulmonary inflammation in the course of neonatal meconium aspiration syndrome (MAS) has been emphasized, the triggering mechanisms and the manifold interplay of the injurious mediators in MAS are still poorly identified. There is yet evidence that human meconium may induce production of proinflammatory agents within the lungs, and that some proinflammatory components of meconium itself, such as cytokines and phospholipase A 2 (PLA 2 ), may additionally contribute to intense inflammation and injury in the meconium-contaminated lung tissue.
3,4 PLA 2 represents a family of ubiquitous enzymes that through cleavage of membrane phospholipids release arachidonic acid, the precursor of proinflammatory eicosanoid. 5, 6 Although PLA 2 may occur as cytosolic (cPLA 2 ) and secretory (sPLA 2 ) types, increasing attention has been paid to the role of secretory PLA 2 as an acute phase protein in inflammatory conditions. 7 In this paper, the present understanding of the role of secretory PLA 2 in acute lung injury, specifically when induced by meconium aspiration, is delineated. A new line of basic and clinical research of MAS, namely the possible contribution of meconiumintroduced secretory PLA 2 to systemic inflammation, is also highlighted.
PLA 2 and acute lung injury
Several lines of clinical and experimental evidence implicate that excess pulmonary PLA 2 activity, through generation of potent vasoactive and proinflammatory lysophospholipids and eicosanoids, 5, 6 may contribute to the progression of various inflammatory lung disorders. [5] [6] [7] [8] [9] In agreement, high blood and pulmonary enzyme activity, correlating with the disease severity, has been found in acute respiratory distress in adults. 10 Although high PLA 2 activity in inflammatory lung injuries is commonly connected with increased release of group II secretory PLA 2 (PLA 2 -II) from macrophages and platelets, 6, 7, 11 group I PLA 2 (PLA 2 -I), secreted by the pancreas, is also known to be expressed and to modulate cellular function in human lungs. 12 Mammalian PLA 2 -I is in fact able to inactivate pulmonary surfactant concentration-dependently through hydrolysis of phosphatidylcholine.
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PLA 2 -I may additionally, independent of the enzyme catalytic activity, stimulate through specific membrane receptor action neutrophil function and cytokine and eicosanoid production from pulmonary cells. 7, 14 Moreover, experimental investigations have shown that exogenously administered PLA 2 -I may induce, most likely through increased pulmonary thromboxane A 2 synthesis, receptor-mediated contractile responses in the airways. 15 It is therefore apparent that PLA 2 activity associated with upregulation of PLA 2 -I may be important in the pathogenesis of acute inflammatory lung injury. Still, variations in the tissue expressions of different PLA 2 enzyme types in the insulted lungs may also have consequences in the clinical course and therapeutic approaches (for example, use of specific PLA 2 inhibitors) of acute lung injuries from various origin.
The role of PLA 2 in meconium-induced lung injury Earlier studies in our laboratory have demonstrated that human meconium has very high catalytic PLA 2 activity, mainly (>90%) due to high concentration of human pancreatic PLA 2 -I. 4 In line with this finding, tissue PLA 2 activity and concentration of human pancreatic PLA 2 in the meconium-contaminated lungs are concentration-dependently elevated and correlate directly with the severity of the meconium-induced lung injury. 4, 16, 17 In these studies, promotion of lung edema formation and neutrophil influx through insufflated human PLA 2 -I, either in soluble form or within meconium, further substantiates the central role of pulmonary PLA 2 -I in the development of lung injury after meconium aspiration. 16, 17 High PLA 2 activity in meconium, mainly due to secretory PLA 2 -I, is additionally shown to be associated with decreased surfactant biophysical activity in the affected lungs. 18 This inactivation could be explained by enzymatic hydrolysis of dipalmitoyl-phosphatidylcholine, the major lipid constituent of surfactant, but also the produced lyso-phosphatidylcholine may have an inhibitory role. 19 Although some experimental data suggest that type I secretory PLA 2 may induce type II PLA 2 expression, 20 challenge of the lungs with high pancreatic PLA 2 activity within aspirated meconium does not seem to influence pulmonary PLA 2 -II production. 16, 17 It is thus conceivable that exposure of the lungs meconium with high pancreatic PLA 2 activity, specifically through aspiration of thick particulate meconium, may markedly participate in propagation of the ensuing pulmonary failure. 17 Yet, the possible involvement of other phospholipases in the development of meconium-induced lung injury remains to be investigated.
Although the above considerations may potentially offer new ways to treat infants with MAS, most of the current therapies of MAS are symptomatic, and their clinical effects have been unsatisfactory and often conflicting.
1 Accordingly, our earlier data indicate that early administration of dexamethasone, known to inhibit stimulated PLA 2 synthesis, 21 does not reduce lung PLA 2 activity or inflammation in experimental meconium aspiration. 22 Alike, some of our preliminary data show that mepacrine, an unspecific PLA 2 inhibitor, does not decrease PLA 2 activity or prevent inflammatory injury, but rather tends to elevate tissue enzyme activity in the meconium-contaminated lungs (P. Kääpä, unpublished observation). Clearly, more investigations are needed before the pathophysiological relevance of PLA 2 in neonatal MAS is revealed.
The role of PLA 2 in systemic inflammatory reaction after meconium aspiration Recent investigations have suggested that the inflammatory injury processes found in MAS may not be restricted to the lungs, but may also result in systemic inflammatory reaction and possible sequelae in extrapulmonary organs. 23 Intrapulmonary meconium exposure is indeed demonstrated to result in systemic complement activation, cytokine release, and activation of circulating neutrophils with production of a variety of biologically active mediators, including reactive oxygen radicals. 1, 23 In line with these findings, our recent studies indicate that pancreatic PLA 2 , contained in high amount in meconium and thereby introduced into the lungs, may be absorbed, at least to some extent, into the pulmonary circulation. 4, 17 In fact, we were able to demonstrate that human pancreatic PLA 2 concentrations in plasma are elevated during the first hours after intratracheal human meconium administration in newborn piglets (Figure 1 ). Similar PLA 2 activation and circulatory release have been recognized in clinical disorders that promote systemic inflammation. 24 Alike, markedly elevated lung and blood PLA 2 activity, correlating with the disease severity, has been found in adults with acute respiratory distress. 10 The systemic inflammatory reaction with systemic release of mediators, such as PLA 2 and cytokines, is supposed to ultimately lead to extrapulmonary organ dysfunction and injury. 24 Recent experimental data from our laboratory in fact indicate that severe meconium aspiration itself, without any complicating incidents, may result in brain tissue injury, specifically in the hippocampus. 25 Nevertheless, it still remains undetermined how often and at what intensity systemic inflammation occurs in connection with meconium aspiration and what is its significance for the outcome of infants with severe MAS.
Conclusions
Taken together, there is a bulk of evidence indicating that intrapulmonary aspirated meconium, specifically in thick particulate form, challenges the lungs with high human pancreatic PLA 2 concentration and activity, and may thereby contribute to pulmonary inflammatory perturbations, systemic inflammatory reactions and eventually distant organ damage. These findings may be amenable to development of new modes of more specific therapeutic approaches.
